Pedro Vilarinho

Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‑CoV‑2 infection. Contact us at team@exogenus-t.com

ExtremoChem is a Portuguese company devoted to the development and commercialization of novel small synthetic molecules for the stabilization of biologicals. ExtremoChem is based on a multidisciplinar team of researchers from the Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa (ITQB) and Faculdade de Ciências da Universidade de Lisboa. The technology is inspired in nature’s ability to sustain life under extreme conditions. New molecules have been synthesised and developed for use as new excipients for the stabilization of proteins. These molecules are analogues of the molecules found in nature, with improved stabilization properties. One of our main strengths is the ability to efficiently develop and test analogues for customized applications. Our main drive now is to deeply impact markets and societies by applying these new products to the most challenging needs of protein stabilization.

Pharma73 is a Portuguese start-up, dedicated to the development, production and commercialization of a new generation of enhanced performance High Functionality Excipients (HFE’s). Pharma73’s Shareholders are Portuguese R&D company 73100, Lda, and Venture Capital Fund FCR ACTEC II, managed by Portugal Ventures. Pharma73’s natural biopolymer products whose unique properties enable their use as high functionality excipients in a multiplicity of pharmaceutical, food and cosmetics products, are obtained through a proprietary fermentation technology. The company was created in October 2011, with the purpose of developing the production of new high functionality excipients from biopolymers produced by microbial fermentation developed from research and development projects developed by it’s R&D teams in research projects executed at the Chemistry Department of Faculdade de Ciências e Tecnologia at Universidade Nova de Lisboa (FCT/UNL), in Lisbon. Since 2011 and up to now, Pharma73 has engaged on the Proof-of-concept stage of its biopolymer production technology platform and is planning market entry of it’s first products in 2019.

Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‑CoV‑2 infection. Contact us at team@exogenus-t.com

ExtremoChem is a Portuguese company devoted to the development and commercialization of novel small synthetic molecules for the stabilization of biologicals. ExtremoChem is based on a multidisciplinar team of researchers from the Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa (ITQB) and Faculdade de Ciências da Universidade de Lisboa. The technology is inspired in nature’s ability to sustain life under extreme conditions. New molecules have been synthesised and developed for use as new excipients for the stabilization of proteins. These molecules are analogues of the molecules found in nature, with improved stabilization properties. One of our main strengths is the ability to efficiently develop and test analogues for customized applications. Our main drive now is to deeply impact markets and societies by applying these new products to the most challenging needs of protein stabilization.

Pharma73 is a Portuguese start-up, dedicated to the development, production and commercialization of a new generation of enhanced performance High Functionality Excipients (HFE’s). Pharma73’s Shareholders are Portuguese R&D company 73100, Lda, and Venture Capital Fund FCR ACTEC II, managed by Portugal Ventures. Pharma73’s natural biopolymer products whose unique properties enable their use as high functionality excipients in a multiplicity of pharmaceutical, food and cosmetics products, are obtained through a proprietary fermentation technology. The company was created in October 2011, with the purpose of developing the production of new high functionality excipients from biopolymers produced by microbial fermentation developed from research and development projects developed by it’s R&D teams in research projects executed at the Chemistry Department of Faculdade de Ciências e Tecnologia at Universidade Nova de Lisboa (FCT/UNL), in Lisbon. Since 2011 and up to now, Pharma73 has engaged on the Proof-of-concept stage of its biopolymer production technology platform and is planning market entry of it’s first products in 2019.